Oak Associates’s Harmony Biosciences HRMY Stock Holding History

Oak Associates’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-9,789	Closed	-$539K	–	141
2022 Q4	$539K	Buy	9,789 +5,122	+110%	+$282K	0.05%	127
2022 Q3	$207K	Buy	+4,667	New	+$228K	0.02%	131

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Oak Associates's HRMY Position: Q1 2023 in Review

Oak Associates sold out of Harmony Biosciences (HRMY) in Q1 2023, closing a stake of 9,789 shares — an estimated $539K sold.

Oak Associates first reported a position in HRMY in Q3 2022 and held it in 2 quarters. The position peaked at $539K in Q4 2022. 217 funds tracked by Wall St. Rank hold HRMY as of Q1 2023.

Oak Associates reported no remaining Harmony Biosciences position as of Q1 2023 after selling out during the quarter.
Oak Associates sold 9,789 Harmony Biosciences shares in Q1 2023, an estimated $539K.
Oak Associates first reported a position in Harmony Biosciences in Q3 2022 and held it in 2 quarters.
Oak Associates's Harmony Biosciences position peaked at $539K in Q4 2022.
217 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2023.

Based on Oak Associates's 13F filing for Q1 2023, filed 11 May 2023.